Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset ...
NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...
Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains ...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of ...
Signs Term Sheet To Acquire Two Clinical-Stage NSCLC Assets. Kairos Pharma (NYSE American: KAPA) announced it has signed a term sheet for a strategic asset acquisition from Celyn Therapeutics Inc., ...
Deep in our cells, a wide range of processes are occurring constantly. These cellular processes rely on enzymes to act as catalysts and set off a series of molecular interactions. There are still many ...
Introduction of a Differentiated Bispecific Nano ADC Positioned to Compete in Major Global Oncology Markets BOSTON, MA, ...
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
Global healthcare infrastructure relies heavily on accurate biochemical diagnostics. The global creatinine test market ...
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
A depression diagnosis may contribute to kidney disease progression for adults with chronic kidney disease, according to study data published in Frontiers in Nephrology. Depression has been linked to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results